Company Mission Agigma's mision is to become a leading provider of New Generation Transdermal Delivery Systems that are based on their cutting edge materials and processing technologies.
Company Profile Founded in 2007 as a Dellaware Corporation, headquartered in New Jersey 10 people, with key specialties onboard. Operations outsourced to strategic partners. Specialized product Development facilities in Denmark Strategic partnerships established in Boston for medical aesthetics and cosmetic surgery. Strategic realtionship with major marketing and Distribution players in the US cosmetic arena in development.
Traditional Transdermal Delivery systems are used for delivery of drugs through the skin (systemic delivery) or into skin layers (topical delivery) carry several limitations:
- Only work for small molecules - Few drugs withstand the manufacturing conditions - Delivery effectiveness is less than 20% ( 80% of the drug remains in the system and is lost)
Agigma's New Generation transdermal delivery systems address these limitations and offer the opportunity to expand the transdermal delivery route ($20B market in the US today) to new applications in new therapeutic areas such as Skin Care, Delivery of Biopharmacecuticals, Active Wound Care...
Agigma's creates proprietary (Patent) transdermal "drug-in-delivery matrix" products of unique material and drug combinations, that can be custom made for specific applications, resulting in controlled release profiles for molecules of large size, with or with out external triggers (such as PH, Light or current).
Breakthrough Product Solutions
Agigma partners with Best-in-Class Cosmetic, Skin-Care or Pharmaceutical companies to jointly develop, test and launch innovative breakthrough products such as:
- Self-Desapearing (TM) patches with immediate wrinkle reduction effect (Vitamin C+Retinol) - High Potency Wound Care Solution (alternatives to injection)
Market Penetration and Business Expansion
Agigma's plan is to enter highly profitable markets in a phased approached, with its partners
Cosmeceuticals in 2H 2009: First partnerships in progress, explosive expansion in 2010
Medical Devices in 2011 : targeting wound care and / or woman's health
Pharmaceuticals in 2013: Focusing on the delivery of large molecules and biopharmaceuticals
Agigma is currently developing business relationships with major skin-care and Cosmeceutical companies to jointly launch new products in 2H 2009 or sooner.
In order to fund some aspects of the new product development and secure tooling for manufacturing, Agigma is looking for partners to provide $425k of growth funding (almost working capital) in the short term, with a <1year ROI.
Agigma is starting a $3-4M Round A financing process to support the development and launch of its second generation of products and scale up manufacturing capabilities.
Please contact us to receive an Executive Summary of the opportunity and meet with Agigma's CEO.